- Home
- LCTX vs AEF Comparison
LCTX vs AEF Comparison
Compare LCTX & AEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- AEF
- Stock Information
- Founded
- LCTX 1990
- AEF 1989
- Country
- LCTX United States
- AEF United States
- Employees
- LCTX N/A
- AEF N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- AEF Finance/Investors Services
- Sector
- LCTX Health Care
- AEF Finance
- Exchange
- LCTX Nasdaq
- AEF Nasdaq
- Market Cap
- LCTX 274.0M
- AEF 264.3M
- IPO Year
- LCTX N/A
- AEF N/A
- Fundamental
- Price
- LCTX $1.73
- AEF $6.54
- Analyst Decision
- LCTX Strong Buy
- AEF
- Analyst Count
- LCTX 4
- AEF 0
- Target Price
- LCTX $4.25
- AEF N/A
- AVG Volume (30 Days)
- LCTX 1.9M
- AEF 92.5K
- Earning Date
- LCTX 11-13-2025
- AEF 01-01-0001
- Dividend Yield
- LCTX N/A
- AEF 7.13%
- EPS Growth
- LCTX N/A
- AEF N/A
- EPS
- LCTX N/A
- AEF 0.57
- Revenue
- LCTX $10,914,000.00
- AEF N/A
- Revenue This Year
- LCTX N/A
- AEF N/A
- Revenue Next Year
- LCTX $176.00
- AEF N/A
- P/E Ratio
- LCTX N/A
- AEF $8.86
- Revenue Growth
- LCTX 76.43
- AEF N/A
- 52 Week Low
- LCTX $0.37
- AEF $4.40
- 52 Week High
- LCTX $1.83
- AEF $5.53
- Technical
- Relative Strength Index (RSI)
- LCTX 69.14
- AEF N/A
- Support Level
- LCTX $1.64
- AEF N/A
- Resistance Level
- LCTX $1.77
- AEF N/A
- Average True Range (ATR)
- LCTX 0.11
- AEF 0.00
- MACD
- LCTX -0.00
- AEF 0.00
- Stochastic Oscillator
- LCTX 75.00
- AEF 0.00
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.